shutterstock_316160420 (1)

Research Programs

Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, scientists at RXi have developed a unique self-delivering RNAi (sd-rxRNA) platform that allows for rapid identification of lead compounds for multiple targets in different therapeutic areas.  Once a target gene of interest with a known sequence is identified, scientists at RXi are able to develop, synthesize and screen sd-rxRNAs in vitro and file intellectual property. RXi's sd-rxRNA platform provides a distinct advantage for the rapid identification of potent compounds as well as the inherent specificity and reduced off target effects when compared to small molecule drugs.